Skip to main content

Andrew Holden, MD, discusses CLI, the DEEPER OUS trial, and initial experience with the novel Temporary Spur Stent System

Andrew Holden, MD, discusses CLI, the DEEPER OUS trial, and initial experience with the novel Temporary Spur Stent System

August 18, 2020

At the 2020 Virtual Amputation Prevention Symposium (AMP), Andrew Holden, MD, presented on initial experiences with the novel Temporary Spur Stent System in the DEEPER OUS trial. Dr. Holden is Director of Interventional Radiology at Auckland City Hospital, Auckland, New Zealand, and associate professor, Radiology, at Auckland University School of Medicine.  

The Temporary Spur Stent System is a novel device for the treatment of infrapopliteal arterial disease, undergoing evaluation of safety and performance in the DEEPER OUS trial. The trial is a multicenter, single arm study, with Dr. Holden’s site being the first to enroll a patient into the study in June, 2019. Efficacy results in the clinical trial out to 6 months “has been very pleasing” thus far.  

Dr. Holden is positive about the use of the device, saying that he sees “no safety concerns,” and “dissection has been unusual and minimal.” Device deployment has been “very easy and reliable.”  

In discussing the benefits of the Temporary Spur Stent system as an alternative to implantable stents, Dr. Holden comments that this device can “facilitate management of longer length lesions, leaving nothing behind.”  

Dr. Holden notes that another benefit to the device is that “we can use any antiproliferative drug,” as the device is uncoated, but creates channels for a subsequent drug-coated balloon (DCB) to deliver drug into the vessel wall. This may be beneficial if there are safety concerns with a particular drug.

Back to Top